Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + CHOP with optional ASCT and selinexor maintenance for newly diagnosed peripheral T-cell lymphoma
ChiCTR2200057942Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: overall response rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2200057942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057942.